AbbVie Inc. (ABBV)
| Market Cap | 388.43B +7.3% |
| Revenue (ttm) | 61.16B +8.6% |
| Net Income | 4.19B -1.2% |
| EPS | 2.36 -1.3% |
| Shares Out | 1.77B |
| PE Ratio | 93.08 |
| Forward PE | 15.12 |
| Dividend | $6.92 (3.15%) |
| Ex-Dividend Date | Apr 15, 2026 |
| Volume | 5,674,488 |
| Open | 226.89 |
| Previous Close | 225.37 |
| Day's Range | 219.44 - 228.62 |
| 52-Week Range | 164.39 - 244.81 |
| Beta | 0.33 |
| Analysts | Buy |
| Price Target | 247.06 (+12.46%) |
| Earnings Date | Apr 24, 2026 |
About ABBV
AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides facial injectables, plastics and regenerative medi... [Read more]
Financial Performance
In 2025, AbbVie's revenue was $61.16 billion, an increase of 8.57% compared to the previous year's $56.33 billion. Earnings were $4.19 billion, a decrease of -1.23%.
Financial StatementsAnalyst Summary
According to 19 analysts, the average rating for ABBV stock is "Buy." The 12-month stock price target is $247.06, which is an increase of 12.46% from the latest price.
News
New York Plastic Surgical Group and Deep Blue Med Spa Named #1 in New York by Allergan Aesthetics for the Second Year in a Row
New York, NY, March 13, 2026 (GLOBE NEWSWIRE) -- New York Plastic Surgical Group (NYPS Group) and Deep Blue Med Spa (DBMS) are proud to announce that they have once again been recognized by Allergan A...
Harbor Health Care ETF Q4 2025 Portfolio Review
Revolution Medicines was a top contributor during the quarter. AbbVie, by contrast, traded largely sideways, as investors continued to assess its post-patent earnings durability. While Eli Lilly deliv...
AbbVie Inc. (ABBV) Presents at Leerink Global Healthcare Conference 2026 Transcript
AbbVie Inc. (ABBV) Presents at Leerink Global Healthcare Conference 2026 Transcript
AbbVie Announces Positive Topline Results from a Phase 1 Multiple Ascending Dose Study of ABBV-295, a Long-Acting Amylin Analog, in Adults
ABBV-295 treatment showed clinically meaningful body weight reduction from -7.75% to -9.79% (least-squares mean) at week 12 (weekly dosing), to -7.86% to -9.73% at week 13 (every other week and monthl...
AbbVie Inc. (ABBV) Presents at TD Cowen 46th Annual Health Care Conference Transcript
AbbVie Inc. (ABBV) Presents at TD Cowen 46th Annual Health Care Conference Transcript
February Dividends With 4 Raises: 1.6% Up To 14.5%
Rose's Income Garden portfolio reached an all-time high, with forward yield dipping slightly to 6% as portfolio value increased. Mastercard stands out with a 14.5% dividend raise, attractive valuation...
AbbVie to Present at the Leerink Partners Global Healthcare Conference
NORTH CHICAGO, Ill., March 3, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) will participate in the Leerink Partners Global Healthcare Conference on Tuesday, March 10, 2026.
AbbVie Announces Positive Topline Results from Phase 3 AFFIRM Study Evaluating SKYRIZI® (Risankizumab) Subcutaneous Induction in Patients with Crohn's Disease
In the Phase 3 AFFIRM study in adults with moderately to severely active Crohn's disease, risankizumab (SKYRIZI®) achieved superiority for the co-primary and ranked secondary endpoints at week 12 for ...
The High Dividend Yield Bull Market: 3 Compelling 6% Yields
High-yield stocks are outperforming, with a clear rotation from growth to value driving strong returns for dividend-focused investors. Safe, high-yielding companies are still trading at discounts. The...
Best Dividend Aristocrats For March 2026
The ProShares S&P 500 Dividend Aristocrat ETF (NOBL) is up 9.39% YTD in 2026, decisively outperforming SPY's 1.08%. Dividend Aristocrats are regaining momentum after a weak 2025, with 55 outpacing SPY...
Health Care Q4 Dividend Roundup: Merck Offers Thicker Dividend Cushion Than AbbVie
Merck & Co. (MRK) is upgraded to buy, driven by improving dividend cushion ratio (DCR) and robust FQ4 2025 earnings recovery. MRK's dividend safety strengthens, with a projected DCR of 2.57x for 2026,...
AbbVie to Present at the TD Cowen 46th Annual Health Care Conference
NORTH CHICAGO, Ill., Feb. 24, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) will participate in the TD Cowen 46th Annual Health Care Conference on Tuesday, March 3, 2026.
AbbVie to invest $380 million to expand US manufacturing in Illinois
AbbVie on Monday said it would invest $380 million to build two new active pharmaceutical ingredient manufacturing facilities at its Illinois campus, expanding its domestic production capacity for its...
AbbVie to Invest $380 Million in North Chicago to Further Expand Active Pharmaceutical Ingredient Manufacturing in the United States
Investment marks continued progress against AbbVie's $100 billion commitment to U.S. research and development (R&D) and capital investments, including manufacturing, over the next decade Two new facil...
U.S. Food and Drug Administration (FDA) Approves Combination Treatment of VENCLEXTA® (venetoclax) and Acalabrutinib for Previously Untreated Patients With Chronic Lymphocytic Leukemia (CLL)
First all-oral, fixed-duration combination regimen approved for previously untreated patients with CLL Approval supported by data from the Phase 3 AMPLIFY trial Regimen offers another option for the p...
AbbVie Declares Quarterly Dividend
NORTH CHICAGO, Ill., Feb. 19, 2026 /PRNewswire/ -- The board of directors of AbbVie Inc. (NYSE: ABBV) today declared a quarterly cash dividend of $1.73 per share.
AbbVie: Dominating Immunology While Building Oncology Upside
None of the Big Pharma players has succeeded in challenging AbbVie's dominance in the immune-mediated inflammatory diseases market. In my view, this is directly related to the near-perfect complementa...
AbbVie Inc. (ABBV) Presents at Piper Sandler Virtual Novel Targets in Immunology Symposium Transcript
AbbVie Inc. (ABBV) Presents at Piper Sandler Virtual Novel Targets in Immunology Symposium Transcript
54 Stocks, 9 Megatrends: My Favorite Places To Be While Capital Is 'Forced'
My top-down strategy targets 'mission-critical' sectors where capital is forced by secular and cyclical tailwinds—data centers, energy, AI, defense, and infrastructure. AI-driven data center and energ...
AbbVie sues US health agency over Botox price controls
AbbVie sued the U.S. Department of Health and Human Services on Wednesday, challenging a decision by the Centers for Medicare & Medicaid Services to impose price controls for Botox.
Abbvie sues US health agency over Botox
Abbvie sued the U.S. Department of Health and Human Services on Wednesday, challenging a decision by the Centers for Medicare & Medicaid Services to select Botox for prescription drug price controls e...
Dividend Kings: No Ideal Buys In February's 57
Dividend Kings remain broadly overvalued, with only a handful approaching fair price despite elevated yields. Three Dividend Kings—Canadian Utilities, Fortis, and Hormel—currently meet the dogcatcher ...
AbbVie: The Market Is Getting It Wrong
AbbVie delivered a resilient Q4 with 10% YoY revenue growth and strong immunology performance, despite a post-earnings stock selloff. Their adjusted EPS grew 25% YoY, beating estimates, while operatin...
AbbVie: Skyrizi And Rinvoq Growth Isn't Everything, But It's A Lot
AbbVie has significantly outperformed prior immunology sales projections, with Skyrizi and Rinvoq now expected to reach $38 billion by 2030. ABBV's oncology and neuroscience pipelines have expanded vi...